Basée au Genopole® d’Evry, InnaVirVax est une société biopharmaceutique spécialisée dans la recherche et le développement de solutions thérapeutiques et diagnostiques de pathologies liées à des dérégulations immunitaires. Autour de la compréhension de telles dérégulations immunitaires, la Société a développé un portefeuille de projets innovants dans les domaines de l’oncologie et du VIH. Crée en 2008, l’entreprise a depuis reçu le soutien du Ministère de l’Enseignement Supérieur et de la Recherche, d’OSEO, de l’Agence Nationale de la Recherche, du Centre Francilien de l’Innovation et des fonds d’amorçage régionaux CapDecisif et G1J Ile-de-France. Plus d’informations sur www.innavirvax.fr.
Location: France, Ile-of-France, Evry
Employees: 11-50
Total raised: $8.8M
Founded date: 2008
Investors 1
| Date | Name | Website |
| - | Paris Regi... | frci-idf.c... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 19.07.2015 | - | $3.9M | - |
| 14.02.2012 | Series B | $4.9M | - |
Mentions in press and media 6
| Date | Title | Description |
| 19.07.2015 | InnaVirVax Raises €3.6M in Third Funding Round | InnaVirVax, an Evry, a Paris biopark-based biopharmaceutical company specialized in research and development of therapeutic solutions for infectious and major chronic diseases, raised €3.6m ($4m) in its third funding round. Backers included... |
| 17.07.2015 | Daily funding roundup - July 17, 2015 | Protagonist Therapeutics bagged $40M; Upstart raised $35M; Courtagen secured $20M CredSimple, a startup building a medical credentialing database, snagged $1.5 million in seed funding to help healthcare and insurance companies manage their ... |
| 16.01.2014 | Biopharma management team ISO growth-stage companies to advise and direct | The co-founders of 6-month-old consulting company NovoBioPharma want to carve a niche for themselves in the area of helping manage and advise growth-stage life science industry companies — an area they view as underserved. Members provide a... |
| 14.02.2012 | InnaVirVax Receives $4.9M Series B | EVRY, FRANCE, Biopharmaceutical company dedicated to the development of therapeutic and diagnostic solutions in pathologies associated with immune dysregulation, announced the closing of a $4.9 million. >> Click here for more fundi... |
| 14.02.2012 | InnaVirVax Closes €3.7M Series B Funding | InnaVirVax, an Evry, France-based biopharmaceutical company dedicated to the development of therapeutic and diagnostic solutions in pathologies associated with immune dysregulation, has closed a €3.7m (approximately $4.9m) Series B funding ... |
| - | Biopharma management team ISO growth-stage companies to advise and direct | The co-founders of 6-month-old consulting company NovoBioPharma want to carve a niche for themselves in the area of helping manage and advise growth-stage life science industry companies — an area they view as underserved. Members provide a... |